2019
Evolution of Medicare Formulary Coverage Changes for Antithrombotic Therapies After Guideline Updates
Dayoub EJ, Ross JS, Shah ND, Dhruva SS. Evolution of Medicare Formulary Coverage Changes for Antithrombotic Therapies After Guideline Updates. Circulation 2019, 140: 1227-1230. PMID: 31567008, DOI: 10.1161/circulationaha.119.040580.Peer-Reviewed Original Research
2016
Fibrinolytic therapy in hospitals without percutaneous coronary intervention capabilities in China from 2001 to 2011: China PEACE-retrospective AMI study
Li J, Li X, Ross JS, Wang Q, Wang Y, Desai NR, Xu X, Nuti SV, Masoudi FA, Spertus JA, Krumholz HM, Jiang L, Group F. Fibrinolytic therapy in hospitals without percutaneous coronary intervention capabilities in China from 2001 to 2011: China PEACE-retrospective AMI study. European Heart Journal Acute Cardiovascular Care 2016, 6: 232-243. PMID: 26787648, DOI: 10.1177/2048872615626656.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionElevation myocardial infarctionFibrinolytic therapyMyocardial infarctionPercutaneous coronary intervention capabilitySequential cross-sectional studiesChina PEACE-Retrospective AMI StudyPrimary reperfusion strategyPercutaneous coronary interventionLittle clinical evidenceCross-sectional studyQuality of careTwo-stage random samplingCoronary interventionHospital delayNeedle timeReperfusion strategySymptom onsetTherapy useClinical evidenceEmergency departmentMedian admissionIdeal patientPatientsWeighted proportion
2012
The Use and Misuse of Thrombolytic Therapy Within the Veterans Health Administration
Keyhani S, Arling G, Williams LS, Ross JS, Ordin DL, Myers J, Tyndall G, Vogel B, Bravata DM. The Use and Misuse of Thrombolytic Therapy Within the Veterans Health Administration. Medical Care 2012, 50: 66-73. PMID: 22182924, DOI: 10.1097/mlr.0b013e3182294092.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedAged, 80 and overBrain IschemiaFemaleFibrinolytic AgentsHealth Services MisuseHealth Status IndicatorsHumansMaleMiddle AgedRetrospective StudiesSocioeconomic FactorsStrokeThrombolytic TherapyTime FactorsTissue Plasminogen ActivatorUnited StatesUnited States Department of Veterans AffairsConceptsVHA medical centersTissue plasminogen activatorVeterans Health AdministrationAcute ischemic strokeEligible patientsStroke patientsIschemic strokeSymptom onsetThrombolytic therapyHealth AdministrationStroke symptom onsetAcute stroke patientsIschemic stroke patientsEligible stroke patientsMedical record reviewLow annual volumeThrombolysis deliveryRecord reviewWrong doseVHA systemClinical conditionsMedical CenterEligible veteransEligibility criteriaPatients